Etiopathogenetic parallels and unresolved issues of pathogenesis of comorbidity COPD and metabolic syndrome (review)
| Autor: | A. P. Zima, Olga V. Voronkova, T. V. Saprina, Ekaterina Bukreeva |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
chronic inflammation
Physiology Endocrinology Diabetes and Metabolism QD415-436 030204 cardiovascular system & hematology Bioinformatics Biochemistry metabolic syndrome chronic obstructive pulmonary disease Pathogenesis 03 medical and health sciences 0302 clinical medicine Endocrinology Internal Medicine Medicine QP1-981 COPD Nutrition and Dietetics business.industry pathogenesis Public Health Environmental and Occupational Health medicine.disease Comorbidity comorbidity 030228 respiratory system Metabolic syndrome business |
| Zdroj: | Ожирение и метаболизм, Vol 17, Iss 3, Pp 292-298 (2020) |
| ISSN: | 2306-5524 2071-8713 |
| Popis: | The review analyzes the etiological and pathogenetic factors (including immunopathogenesis factors) of chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MS), cites data on clinical and pathogenetic characteristics of combined pathology, emphasizes the commonality of risk factors and individual links of pathogenesis in syntropy.The clinical and pathogenetic features of the comorbidity of COPD and MS are closely related to the severity of chronic “metabolic” inflammation induced by elements of adipose tissue. Functional and biochemical disorders recorded in metabolic syndrome (insulin resistance, hyperglycemia, dyslipidemia) are considered as factors contributing to dysfunction of the components of innate and adaptive immunity.The review formulates a number of unresolved issues of the pathogenesis of comorbid pathology, the study of which is necessary to search for the mutual aggravating effect of COPD and MS mechanisms. In view of the clinical and laboratory metabolic syndrome equivalents variety, the authors emphasize the relevance of future studies of the pathogenetic features of chronic inflammation associated with the comorbidity of the main components of metabolic syndrome and COPD, to develop effective methods of prevention and pathogenetic therapy of comorbid pathology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|